dociparstat sodium (CX-01) / Cantex Pharma, Chimerix  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
Chimerix_COVID-19: Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

Not yet recruiting
3
450
US
dociparstat sodium (CX-01) - Chimerix
Cantex, Chimerix
Severe COVID-19
 
 
NCT04571645: Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Terminated
3
9
US
Dociparstat, DSTAT, CX-01, 2-0,3-0 desulfated heparin, ODSH, dociparstat sodium, Control, 0.9% Normal Saline, Normal saline, Sodium chloride 0.9%
Chimerix
Acute Myeloid Leukemia
05/22
05/22
NCT04389840: Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Terminated
2/3
27
US
Dociparstat sodium, DSTAT, CX-01, 2-0,3-0 desulfated heparin, ODSH, Placebo, Normal saline, Sodium chloride 0.9%, 0.9% Normal Saline
Chimerix
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
05/21
05/21

Download Options